Figure 7

OAC TCM and Pyrazinib (P3) treated TCM significantly reduced expression of CD83 but did not alter the expression of PD-L1, CD40, HLA-DR or CD54 expression on monocyte derived dendritic cells following stimulation with LPS. The effect Pyrazinib (P3) and Pyrazinib (P3) treated TCM on the expression of dendritic cells maturations markers was assessed by flow cytometry. (A) CD83 expression on monocyte derived dendritic cells following incubation with LPS- and LPS + M199, 0.1% DMSO + LPS, 10 µM Pyrazinib (P3) + LPS, 0.1% DMSO treated OAC TCM + LPS and OAC TCM treated with Pyrazinib (P3) + LPS. (B) PD-L1 expression on monocyte derived dendritic cells following incubation with LPS- and LPS + M199, 0.1% DMSO + LPS, 10 µM Pyrazinib (P3) + LPS, 0.1% DMSO treated OAC TCM + LPS and OAC TCM treated with 10 µM Pyrazinib (P3) + LPS. (C) HLA-DR expression on monocyte derived dendritic cells following incubation with LPS- and LPS + M199, 0.1% DMSO + LPS, 10 µM Pyrazinib (P3) + LPS, 0.1% DMSO treated OAC TCM + LPS and OAC TCM treated with 10 µM Pyrazinib (P3) + LPS. (D) CD54 expression on monocyte derived dendritic cells following incubation with LPS- and LPS + M199, 0.1% DMSO + LPS, 10 µM Pyrazinib (P3) + LPS, 0.1% DMSO treated OAC TCM + LPS and OAC TCM treated with 10 µM P3 + LPS. (E) CD40 expression on monocyte derived dendritic cells following incubation with LPS- and LPS + M199, 0.1% DMSO + LPS, 10 µM Pyrazinib (P3) + LPS, 0.1 DMSO treated OAC TCM + LPS and OAC TCM treated with 10 µM Pyrazinib (P3) + LPS. LPS stimulation indicated by (+). Wilcoxon signed rank t-test, *p < 0.05,***p < 0.001. Data expressed as + SEM.